Suggested remit: To appraise the clinical and cost effectiveness of luspatercept within its marketing authorisation for treating anaemia in non-transfusion dependent beta-thalassaemia.
 
Status Awaiting development
Decision None selected
Process STA 2018
ID number 3870

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
11 February 2022 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia. Please note that following on from information received from the company the timelines for this appraisal are to be confirmed. NICE will continue to monitor the situation and will update interested parties as and when the situation changes.
10 November 2021 - 08 December 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual